Oral dysaesthesia associated with obinutuzumab - a case report

Area of Science:

• Oncology
• Immunotherapy
• Oral Medicine

Background:

• Oral dysaesthesia is a chronic pain condition impacting quality of life.
• Its multifactorial nature presents diagnostic challenges for clinicians.
• Cancer immunotherapy is increasingly common, with patients potentially requiring dental care.

Purpose of the Study:

• To report the first case of oral dysaesthesia associated with obinutuzumab therapy.
• To discuss the clinical findings and investigations for this side effect.
• To review the evidence linking immunotherapy to oral dysaesthesia.

Main Methods:

• Case report of a patient treated with obinutuzumab for follicular lymphoma.
• Detailed clinical history and chairside examination.
• Review of existing literature on immunotherapy-induced oral dysaesthesia.

Main Results:

• The patient experienced severe, therapy-limiting oral dysaesthesia during obinutuzumab treatment.
• Clinical findings and investigations confirmed the diagnosis of oral dysaesthesia.
• Literature review indicates a potential association between immunotherapy and oral dysaesthesia.

Conclusions:

• Oral dysaesthesia can be a significant side effect of obinutuzumab immunotherapy.
• Awareness among dental clinicians is crucial for managing patients on novel cancer therapies.
• Further research is needed to understand and manage immunotherapy-associated oral dysaesthesia.